Browsing Tag
Mark Enyedy
2 posts
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical…
ImmunoGen secures up to $175m from Pharmakon Advisors to accelerate oncology growth
ImmunoGen secures up to $175M in non-dilutive funding from Pharmakon to fuel Elahere’s launch and expand its next-gen ADC pipeline. Read the full breakdown.